The discovery that estrogen receptors (ERs) are involved in bone cells' responses to mechanical strain offered the prospect of establishing the link between declining levels of circulating estrogen and the progressive failure of the mechanically adaptive mechanisms that should maintain structurally appropriate levels of bone mass in age-related and post-menopausal osteoporosis. Such clarification remains elusive but studies have confirmed ligandindependent involvement of ERs as facilitators in a number of the pathways by which mechanical strain stimulates osteoblast proliferation and bone formation. The presence of a and b forms of ER that oppose, supplement or replace one another has complicated interpretation of studies to identify their individual roles when both are present in normal amounts. However, it appears that, in mice at least, ERa promotes cortical bone mass in both males and females through its effects in early members of the osteoblast lineage, but enhances loading-related cortical bone gain only in females. In addition to its role as a potential replacement for ERa, and modifier of ERa activity, the less well-studied ERb appears to facilitate rapid early effects of strain including activation of extracellular signal-regulated kinase and downregulation of Sost in well-differentiated cells of the osteoblast lineage including osteocytes. If these different roles are substantiated by further studies, it would appear that under normal circumstances ERa contributes primarily to the size and extent of bones' osteogenic response to load bearing through facilitating anabolic influences in osteoblasts and osteoblast progenitors, whereas ERb is more involved in the strain-related responses generated within resident cells including osteocytes.
It has long been recognized that age-related decline in estrogen levels, notably but not exclusively in women after the menopause, is associated with loss of bones' ability to continue to adjust their mass and architecture to maintain their resistance to fracture. The mechanisms by which bone architecture is normally matched to customary loading is commonly referred to as the mechanostat. The initial in vitro finding that blocking ER activity not only reduces osteoblasts' proliferative response to estradiol, but also their similar response to mechanical strain, potentially offered a mechanistic explanation for the involvement of estrogen signaling in the mechanostat. 1 This possibility was reinforced by in vivo confirmation 2 that the absence of ERa activity in ERa knockout mice was associated with a reduced osteogenic response to loading.
The hypothesis derived from these studies 3 envisaged that it was not any effect of estrogen itself, but ligand-independent ER activity within bone cells' responses to strain that influenced the efficacy of bone cells' adaptive response to load bearing. ER levels are substantially regulated by estrogens, 4 the availability of ERa in resident bone cells is normally low compared with that in other estrogen responsive cells, [5] [6] and strain-related responses are increased by transfection of additional ERa. 7 Thus, reduced ER levels as a result of reduced circulating estrogens, could become a limiting factor in bone cells' responses to load-induced mechanical strain in their surrounding tissue. Reduction in the effectiveness of these responses could account for the progressive ineffectiveness of bone cells to maintain structurally appropriate bone mass and architecture in post-menopausal osteoporosis in women, and age-related osteoporosis in both men and women.
The importance of osteoporosis, and the therapeutic potential of being able to modify ER function with one of the many selective estrogen receptor modulators, has encouraged investigation of the roles of the ERs in bone biology and the processes by which strain in bone tissue is transduced into stimuli for adaptive (re)modeling. These have ranged from association studies in humans, through study of the normal and adaptive phenotype of a number of genetically modified mice, to a larger number of cell-based studies in vitro.
In Vivo Studies in Humans and Animals: the Confounding Effects of ERa and ERb
A critical role for ERa in human skeletal biology was first demonstrated by the report of a male patient harboring a homozygous loss-of-function mutation of ERa who developed tall stature and osteopenia with a large endosteal circumference and low trabecular bone mass. [8] [9] Studies on the effects of the ERa and ERb isoforms in humans at the population level have relied on establishing associations between genetic polymorphisms and measurable phenotypes such as decreased bone mineral density and fracture risk. 10 ERa polymorphisms influence bone gain during exercise intervention 11, 12 and genetic studies suggest that polymorphisms in the two ERs interact with each other, and with polymorphisms in the insulinlike growth factor-1 (IGF1) gene, to modify the risk of fracture, 13 a finding consistent with well-established molecular cross-talk between these receptors. 14 Nevertheless, the few studies on ER dynamics associated with age and declining estrogen in bone cells in humans 15 are insufficient to draw any substantial conclusions. Most of the work in this area relies instead on animal models.
Interactions between the effects of ERa and ERb, together with 'incomplete' deletion of each ER in early knockout models, have confounded studies attempting to establish separate and unambiguous roles for ERa and ERb, as reviewed in detail elsewhere. [16] [17] The continued expression of truncated ERs in early knockout models rendered them incomplete. Thus, sufficient expression of the ERa ligand-binding activation function (AF)-2 domain was present in double ERa/ERb knockout mice to enable estradiol to stimulate similar increases in their cortical, but not trabecular, bone mass to wild type (WT). 18 Nevertheless, this early finding is consistent with the recent demonstration that mutation of the ERa AF-2 domain in female mice prevents estradiol-induced cortical and trabecular bone gain, whereas deletion of the AF-1 domain only prevents cortical bone gain following treatment with a high dose of estradiol. 19 In studies using 'complete' global knockout mice, deletion of both ERa and ERb prevented any significant effect of estradiol treatment on trabecular bone mass or turnover, whereas estradiol did exert effects when either receptor was present. 20 These analyses of the effects of estradiol treatment in ovariectomized mice lacking one of both ER isoforms suggest that in female mice ERb mediates inhibitory effects of estradiol on bone turnover and facilitates ERamediated responses to estradiol treatment. 20 A further complication in studies involving knockout of the ER receptor has been the resulting high levels of circulating estrogen in ERa, but not ERb, knockout mice. 21 Similarly, whereas IGF1 is reduced in ERa À / À female mice it is elevated in those lacking ERb, 18 potentially exerting estrogen-independent osteogenic effects including the role of IGF1 in the mechanostat, which is facilitated in osteoblastic cells subjected to mechanical strain through non-genomic activity of ERa. 22 The importance of non-genomic ER signaling in bone has been extensively studied, in part thanks to the development of the global 'non-classical ER knock-in' mouse, which express an ERa unable to bind DNA. This 'knock-in' is associated with lower cortical and trabecular bone mass in the tibia of 3-monthold female mice. 23 In a different model, also investigating non-genomic ER signaling, treatment of female mice with an estradiol-dendrimer complex, which selectively activates membrane-initiated signaling, was as effective as estradiol at inhibiting ovariectomy-induced bone loss in cortical, but not cancellous bone. 24 These findings suggest that, at least in female mice, bone mass is influenced by a balance between classical and non-classical ERa signaling.
This complexity of ERa signaling is derived not only from variable interaction with ERb, but also by the expression in bone cells of various different ERa isoforms. In addition to the classical 66-kDa full-length ERa (ERa66), osteoblast-like cells also express ERa46 and ERa36. ERa46 lacks the AF-1 domain and strongly inhibits the genomic action of ERa66 in osteoblastic cells, 25 potentially promoting non-classical ER knock-in-like signaling. ERa36 lacks both the complete AF-1 and part of the AF-2 domains so it only contains a ligand-binding domain, the DNA-binding domain and a short sequence unique to this ERa isoform. Unlike ERa66, which is predominantly localized in the nucleus, ERa36 is targeted to the cell membrane from where it initiates non-genomic signaling. 26 The roles of these isoforms of ERa have been most extensively studied in breast cancer, in which ERa36 and ERa46 appear to have opposite effects. High ERa36 expression has been associated with more proliferative phenotypes and resistance to tamoxifen therapy, whereas ERa46 expression conveys sensitivity to tamoxifen. [26] [27] In bone, ERa36 expression has been found to be lower in osteoblasts, and osteoclasts from osteoporotic than similarly aged non-osteoporotic postmenopausal women. 28 In cultures from non-osteoporotic postmenopausal women, low-dose estradiol triggered osteoblastic cell proliferation while promoting osteoclastic cell apoptosis. These responses were not observed in similarly derived cultures from osteoporotic women. However, transfection of exogenous ERa36 rescued both osteoblast proliferation and osteoclast apoptosis in response to low-dose estradiol treatment in cultures from osteoporotic women. 28 Studies such as these are at present too few, and their results too ambiguous, for any firm conclusions to be drawn regarding contribution of the ERs to clinical osteoporosis.
ERa Promotes Cortical Bone Mass Through its Action in Early Progenitors
Notwithstanding, the potential for different ERa isoforms to exert different effects, complete deletion of ERa selectively at specific stages of the osteoblast lineage and in osteoclasts, has provided a detailed map of its action in different bone compartments. Such a map is not yet available for ERb. Two different models (Cathepsin K-cre and LysM-cre) have established that ERa expression in osteoclasts mediates the protective effects of estrogens in female trabecular bone, but not in male trabecular bone or in cortical bone of either sex. [29] [30] A recent report by Almeida et al. 31 provides a detailed analysis of bone phenotypes of mice in which ERa was deleted at different stages of the osteoblast lineage including mesenchymal progenitors using Prx-cre, early osteoblasts/chondrocytes using osterix-cre or committed osteoblasts using Col1a1-cre. Prx-cre-mediated deletion of ERa results in lower cortical thickness in both male and female mice at 6-8 weeks of age.
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Eight-week-old Prx-cre female mice have reduced bone formation rate at the periosteal, but not the endocortical surface. This effect persists in female, but not in male, mice up to 28 weeks, the latest time point reported. Trabecular bone mass is also reduced in female Prx-cre mice because of a reduction in trabecular number at 12 weeks of age, but not at other time points tested. 31 Deletion of ERa later in the osteoblast lineage using an osterix-cre reduces cortical thickness in 24-week-old female mice with floxed ERa, whereas Col1A1-cre does not alter cancellous or cortical bone mass in 12-or 26-week-old female mice. 31 These findings suggest that the role of ERa in the attainment of cortical bone mass in female mice involves its activity in early members of the osteoblast lineage. This is consistent with the finding that loss of ERa in osteocytes using DMP1-cre does not alter female bone mass in any compartment. 32 In contrast, deletion of floxed ERa in mature osteoblasts using an osteocalcin-cre model reduces both cortical and trabecular bone mass in female mice. 33 These differences are more evident in young adult female mice; whereas the conditional knockout mice have lower tibial cortical bone volume and bone volume per tissue volume at 3.5 and 6 months neither of these parameters are significantly different from WT by 12 months because of greater loss of bone mass in the WTs. 33 Histomorphometric analysis of bone formation and resorption in vertebral trabecular bone indicates that both processes are reduced in the osteoblast ERa-deleted mice. 33 In males, osteocalcin-cre-mediated ERa deletion only significantly reduces trabecular bone mass at 6 months of age, not earlier, 33 although in a separate report DMP1-targeted deletion reduces trabecular bone volume at 11 weeks of age. 32 It is puzzling that ERa deletion in osteocytes is associated with lower trabecular bone mass in male mice, 32 whereas its deletion earlier in the lineage (therefore, presumably including deletion in osteocytes) 31, 33 has no detectable effect on this compartment. Taken together, these studies suggest that ER expression in osteocytes in males appears also to contribute to trabecular bone mass, whereas the osteogenic effects of ERa expression on cortical bone accrual in female mice relate to its actions in early osteoblasts, not terminally differentiated osteocytes ( Figure 1) . This is consistent with in vitro findings that ERa can promote osteoblast differentiation 31 and facilitates proliferation following estradiol, 1 Wnt3 31 and mechanical strain. 1, 34 The Ligand-Independent Role of Contribution of ER to the Mechanostat
The important role of ERa in the control of cortical bone, in female mice at least, is consistent with the initial finding by Lee et al. 2 that the absence of ERa blunts the increase in cortical bone formation associated with short periods of artificial loading. [35] [36] [37] In a subsequent study, incomplete deletion of ERb was found to reduce the osteogenic response in the ulna of female mice similarly to ERa deletion, 37 suggesting that the two ERs complemented each other's function in the mechanostat. However, studies using more complete ERb knockout mice suggest an enhanced response to loading in the cortical bone of both male and female mice 36 (Figure 2) .
In trabecular bone, global deletion of ERa does not impair the osteogenic response to loading in female mice and, paradoxically, increases cortical and trabecular bone gain following loading in male mice relative to WT controls. 36 In such experiments, inferences of adaptive responses to artificial loading in trabecular bone are limited because current techniques are unable to accurately measure or assess the strain magnitudes in the trabeculae of bones subject to either experimental or natural loading. This may be a significant deficiency as deletion of ERa or ERb increases trabecular bone mass in female mice, 36 such that strains engendered in this compartment may be lower than those generated by similar loads in WT controls.
In female mice, differences in serum estradiol between WT and transgenics can also alter ER-mediated effects in response of bone to loading. Windahl et al. 35 investigated this by ovariectomizing mice before subjecting their tibiae to loading. Ovariectomy did not alter the loading-related increase in bone formation at either the periosteal or endosteal surface, whereas global deletion of ERa significantly reduced the increase in formation on both surfaces. 35 This ligand independency of Figure 1 Estrogen receptor a (ERa) expression increases bone mass in different bone compartments through its action in different cell types. ERa deletion in osteoclasts (Cathepsin K-cre and LysM-cre) reduced trabecular bone mass in female, but not in male, mice, whereas its deletion in osteocytes (DMP1-cre) reduced trabecular bone mass in male but not in female mice. Cortical bone in female mice was reduced by deletion of ERa in osteoblasts (Osteoclacin-cre, osterix-cre) and pre-osteoblasts (Prxcre). In male mice, deletion of ERa in osteoblasts (osteoclacin-cre, Col1A1-cre) had no effect on male cortical bone, whereas its deletion in pre-osteoblasts (Prx-cre) reduced cortical thickness.
Figure 2
Schematic representation of the influences of estrogen receptor a (ERa) and ERb on loading-related bone gain in cortical and trabecular bone of male and female mice. Global ERa deletion has been associated with reduced cortical bone gain in female mice but increased cortical bone gain in males following loading. [35] [36] [37] Complete deletion of ERb increased trabecular bone gain in females and cortical bone gain in both males and females following loading, 36 whereas in an earlier study incomplete ERb deletion impaired cortical bone gain following loading in the ulna of female mice. 37 Deletion of either ER does not alter trabecular bone gain following loading in male mice, 36 but the effects of double ER deletion or cell type-specific deletions have not been investigated.
Er functions in adaptive bone (re)modeling GL Galea et al contribution of ERa to the mechanostat is further substantiated by analyzing the response to loading in mice expressing a truncated ERa lacking specific receptor domains. The AF-2 domain of ERa contains the ligand-binding site, whereas its AF-1 domain mediates interactions with other proteins. Relative to WT, female mice lacking AF-1 show a lower increase in bone formation at both periosteal and endosteal surfaces in response to loading. However, mutation of the AF-2 domain did not significantly reduce periosteal or endosteal bone formation relative to the response in WT littermates (although the percentage increase in bone area in WT mice of the AF-2 colony was lower than that observed in the AF-1 colony). 35 Involvement of the AF-1 domain of ERa in osteogenesis stimulated by loading is the opposite from that seen following activation of the ERs with their endogenous ligand, estradiol. The increase in cortical thickness following high-dose estradiol administration to ovariectomized mice requires the AF-2 domain of ERa but not its AF-1 domain, whereas the increase in trabecular bone following estradiol treatment requires a fully functional ERa containing both AF-1 and AF-2. 19 However, experimental studies investigating responses of bone to high doses of estradiol must be interpreted with caution, and it remains to be determined how relevant they are for determining the role of ERs in osteoporosis. Notwithstanding, taken together, these findings support an important role for ERa acting through its ligandindependent AF-1 domain to facilitate functional adaptation to loading in the cortical bone of female mice (Figure 3) .
Does Contribution of ER to the Mechanostat Extend to Mature Osteocytes?
Ligand-dependent contributions of ER to the effects of estrogen are systemic, whereas its ligand-independent contributions to the mechanostat are local and site specific. In vitro, in rat osteoblastic cells subjected to strain ERa can be ligand independently activated through AF-1 phosphorylation at S122 involving protein kinase A and ERK. 38 ERa activation may lead to activation of genomic estrogen response elements, 7 promote interleukin-11 upregulation, 35 and facilitate local strain-induced osteoblast proliferation. 34, 39 Osteoblast proliferation is initiated very rapidly, within 30 min following exposure to strain, 34 which is consistent with ERa phosphorylation increasing by this time. 38 Proliferation of osteoblastic cells has been assumed to be a necessary prelude to the increased new bone formation normally associated with bone gain following in vivo loading. [40] [41] Increasing the expression of ERa in osteoblastic cells increases their proliferation following strain, 7 suggesting that the availability of ERa may normally limit this response.
Osteoblastic proliferation following strain involves a number of signaling pathways including IGF 1 and canonical Wnt signaling. 34 ERa interacts with both these pathways, sensitizing the IGF receptor to ambient IGFs leading to activation of AKT signaling and stabilizing the Wnt secondary mediator b-catenin, 22 as well as facilitating b-catenin translocation to the nucleus. 42 These, and other functions of the ERs in osteoblastic cells' responses to strain, are represented in Figure 4 . Even in the absence of strain, there is increasing evidence that ERa modulates Wnt signaling. Osteoblastic cells lacking ERa are less proliferative basally and do not proliferate as vigorously following treatment with canonical Wnts as cells derived from WT mice. 31 Almeida et al. also observe that knockdown of ERa greatly reduces the induction of TCF-luciferase reporter construct activation by Wnt3, 31 which is consistent with the previous report that ERa interacts with TCF-4 in osteoblastic cells. 43 Furthermore, the increase in alkaline phosphatase activity stimulated by Wnt3 in cells from WT mice is absent in cells from ERa-deleted mice, 31 suggesting that ERa is an intrinsic component of Wnt signaling involved in regulatory processes unrelated to mechanical strain. However, strainrelated effects operate within a context of non-strain derived influences (such as growth 44 ) that may have a profound effect on the outcome. This may represent another influence of ERa on the mechanostat as Wnt signaling is a key determinant of bone mass involved in the adaptation of both cortical and trabecular bone to loading in both male and female mice. 45 Although the findings referred to indicate a potentially important role for ERa in the early anabolic responses of osteoblasts to strain-related stimulation, they do little to clarify the question of which processes ERa ligand independently facilitates in cortical osteoblasts rather than in osteocytes. Osteocytes are the most numerous resident strain-sensitive cells in the skeleton and are regarded by many as being the primary orchestrators of functional (re)modeling. If contributions of ERa to the mechanostat predominate in members of the osteoblast lineage able to proliferate and/or differentiate, this would explain why its deletion in osteocytes using DMP1-cre does not alter the osteogenic response to loading in the cortical bone of female mice. 32 However, if the role of ERa is confined to the signaling processes involved in converting resident bone cells' strain-related experience into an osteogenic (re)modeling response, does either ERa or ERb have a role in the earliest processes of strain transduction by which exposure to strain initiates the signaling cascades, which culminate in mechanically appropriate (re)modeling?
Separate Roles for ERb in the Mechanostat?
Mechanistically, ERb expression in bone suppresses the expression of a set of genes following estrogen treatment when Figure 3 The osteogenic effects of loading and estrogen (E2) on trabecular and cortical bone of female mice are differentially mediated by its activation function 1 (AF1) and AF2 domains. Deletion of either the AF1 or AF2 domains of estrogen receptor a (ERa), or complete ERa deletion, does not impair the osteogenic response of loading on female trabecular bone, whereas deletion of either domain reduces trabecular bone gain following treatment with estrogen. In cortical bone, deletion of the AF1 domain impaired the osteogenic response to loading, whereas only deletion of the AF2 domain impaired the increase in cortical bone mass following treatment with estrogen.
Er functions in adaptive bone (re)modeling GL Galea et al ERa is present, but promotes expression of a subset of genes when ERa is deleted. 46 This is consistent with the finding that ERb suppresses basal osteoblastic cell proliferation mediated by ERa 34 and that osteoblastic cells from ERb knockout mice show a greater ERa-mediated proliferative response following exposure to strain than cells similarly derived from their WT counterparts. 47 Thus, in proliferative osteoblasts in which roles of ERa are facilitatory, the influence of ERb on the mechanostat may be to suppresses bone gain triggered by loading. This inhibitory role alone cannot explain the repeated association between polymorphisms in ERb with lower bone mass in humans, 10, 13 and the reduced osteogenic response to loading initially observed in ERb À / À female mice. 37 Although global ERb À / À models have not shown low-bone-mass phenotypes, findings in these models must be interpreted with caution given increased circulating levels of IGF1 18 and potentially compensatory upregulation of ERa. 48 Determining the potentially separate roles of ERa and ERb in osteocytes has been complicated by the lack of a suitable cell model system expressing markers of both late osteocyte differentiation and strain sensitivity. ERa and ERb independently mediate strain-induced activation of ERK signaling in Figure 4 Schematic representation of the involvement of estrogen receptor (ER) in signaling pathways activated by mechanical stimulation of osteoblastic cells. Membraneinitiated signaling events are grouped temporally from stretch-activated calcium channels (SACaC) activated within seconds, to voltage-gated calcium channels (VGCaC), integrins including a5b1/3, ATP's P2 receptors, connexion (Cx)43 hemichannels, PGE2's EP receptors, the primary cilium (1ary Cil) and the insulin-like growth factor (IGF) receptor. The ERs (red) are emphasized to illustrate their contribution to several pathways. Timing of intracellular signaling is difficult to dissect because of cross-talk between different pathways but a general timeframe is indicated (left). AKT, protein kinase B; AR, androgen receptor; cGMP, cyclic guanosine monophosphate; CREB, cAMP response element binding protein; eNOS, endothelial nitric oxide synthase; EP, E series prostaglandin receptors; FAK, focal adhesion kinase; GSK3b, glycogen synthase kinase 3b; IL, interleukin; JNK, c-Jun Nterminus kinase; mTOR, mammalian target of rapamycin; NF-kB, nuclear factor kB; PGE2, prostaglandin E2; PI3K, phosphoinositide 3-kinase; PKC, protein kinase C.
Figure 5
Schematic illustrating the roles of estrogen receptor a (ERa) and ERb at different stages of the osteoblastic lineage. Early osteoblasts can proliferate or differentiate. ERa promotes their proliferation 28, 39 and either promotes 31 or suppresses differentiation. 50 There is evidence that ERb promotes differentiation while inhibiting proliferation. ERb and ERa both contribute to matrix production, and ERb also selectively regulates genes associated with cell migration. In osteoblastic cells exposed to mechanical strain, ERa facilitates other osteogenic signaling pathways, specifically insulin-like growth factor (IGF), ERK and Wnt/b-catenin signaling. ERa and ERb also contribute to anti-apoptotic signaling. Both ERs may also influence osteoclastogenic cytokine expression by osteoblastic cells. This diagram is based on our previous report. 34 b-cat, beta-catenin; LRP, lowdensity lipoprotein receptor related protein.
Er functions in adaptive bone (re)modeling GL Galea et al osteocytic MLO-Y4 cells, potentially related to the antiapoptotic effect of strain in these cells. 49 ERK signaling in Saos-2 human osteoblastic cells, which both express and secrete the Wnt antagonist Sost/sclerostin, mediates Sost downregulation following strain. 34 The requirement in these cells for ERb, and not ERa, to enable strain to downregulate Sost 34 is consistent with osteocyte ERa being dispensable for loading-related cortical bone gain in female mice 32 and suggests a separate role for ERb. This needs to be substantiated in normal mature osteocytes in situ.
It is clear that the role of ERb in adaptation of bone to loading remains controversial and, compared with ERa, under-studied. The realization that ERb could have a separate role from that of ERa, as well as potentially modulating ERa activity in different cell types ( Figure 5) , implies that it is necessary to review carefully all previous studies that did not specifically distinguish between such potential separate effects to ensure that the findings are not over or misinterpreted.
Summary
Taken together, the studies reviewed here confirm that both ERa and ERb make significant contributions to the mechanisms involved in the regulation of bone mass and architecture. These contributions are site and gender specific and include those by which mechanical strain in bone tissue influences the adaptive (re)modeling involved in loading-related control of bone mass and architecture.
Work by Almeida et al. 31 has shown that ERa promotes cortical bone mass through the action of early osteoblast progenitors. This action may be reproduced in responses of bone cells to mechanical strain as it is fairly clear from a number of studies that ERa facilitates a number of the early strainrelated pathways in osteoblastic cells, and the proliferation of osteoblasts in their response to mechanical strain. As elegantly confirmed by Windahl et al., 35 these contributions of ERa do not require the presence of either estrogens or the ERa's AF-2 ligand-binding domain. Absence or deficiency of ERa activity in humans would be expected to downregulate the anabolic response to strain-related stimulation, possibly contributing to osteopenia and bone fragility.
ERb has been far less well studied than ERa and its role has been assumed to be primarily to either oppose actions of ERa, act together with ERa, or substitute for ERa in its absence. It may, however, be that ERb makes a separate contribution to the mechanostat in the earliest strain-related responses of more differentiated bone cells including osteocytes. The actions of ERb clearly require further study.
The most obvious, and most important, deficiency in the study of the effect of the estrogen receptors on the control of bone architecture is the absence of good data from humans. Without such data the potential implications of ER activity in ensuring that bone structure matches bone loading will go un-investigated and the therapeutic potential of ER modification by selective estrogen receptor modulators unexplored.
